374 related articles for article (PubMed ID: 26222274)
1. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
4. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y
BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
10. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
11. Progress in the mechanism and drug development of castration-resistant prostate cancer.
Zuo M; Xu X; Li T; Ge R; Li Z
Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials.
Tunio M; Al Asiri M; Al Hadab A; Bayoumi Y
Drug Des Devel Ther; 2015; 9():5291-9. PubMed ID: 26451085
[TBL] [Abstract][Full Text] [Related]
15. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
16. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
18. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
19. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
20. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
